Reducing Cardiovascular Risk Through Non-Statins


As cardiovascular disease becomes more manageable and preventable, selecting the most appropriate therapy is key. Learn best practices on the management of cholesterol and dyslipidemia from the American College of Cardiology 2017 Expert Consensus Decision Pathway and the National Lipid Association 2017 recommendations. You will also hear from experts about the role of non-statin therapies, including PCSK9 inhibitors, in cardiovascular risk reduction.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Discuss the evidence evaluating the efficacy and safety of non-statin therapies in patients with dyslipidemia, including the impact on long-term cardiovascular outcomes.
  2. Describe appropriate use of non-statin therapies based on recommendations from authoritative national organizations. 
  3. Identify patients who may be appropriate for treatment with non-statin therapies.  
  4. Develop monitoring strategies to assess the efficacy and toxicity of PCSK9 inhibitors.


This activity is supported by an independent educational grant from Pfizer.

Kim Birtcher,
University of Houston College of Pharmacy
Joseph Saseen, PharmD, FCCP
Learning Level: Level 2
Track: Specialty Pharmacy, Clinical Patient Care and Services
Session Time Slot(s): 
Sunday, March 18
1:00 PM - 2:30 PM
Music City Center - Room 106A-C
ACPE Pharmacist: 0202-0000-18-049-L01-P
CEUs Pharmacist: 0.15
Activity Type: